Cordis Makes Strategic Investment in E2, a developer of Next-Generation Thrombectomy Devices
MIAMI LAKES, Fla., April 5, 2022 /PRNewswire/ -- Cordis today announced a strategic investment venture that will expand the scope of the global cardiovascular technology company into the Venous Thromboembolism Market (VTM) with a strategic investment in Endovascular Engineering ("E2"), a developer of next-generation thrombectomy devices to treat patients with Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
- "Our investment in E2 positions Cordis at the vanguard of innovation in venous interventions," said Duke Rohlen, Executive Chairman of Cordis and CEO of Cordis-X, an independent accelerator created to drive innovation and growth for Cordis.
- "We are proud to support the team's efforts to define a new standard of care for patients suffering from thromboembolism."
- Cordis is partnering with SantVentures and another strategic investor in the E2 transaction.
- The investment in E2 supports Cordis' legacy as a leader in creating lifesaving cardiovascular technologies."